Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209156 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01209156 is a Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 11 participants.
The verdict
NCT01209156, a Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess PBR-111 positron emission tomography (PET) imaging as a tool to detect microglial activation in the brain of Alzheimer disease (AD) research participants and age- and gender-matched healthy volunteers.
Interventions
- DRUG [18F] PBR111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209156
The ClinicalTrials.gov registry entry for NCT01209156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] PBR111 is the first listed.
NCT01209156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209156 about?
NCT01209156 is a clinical study titled "Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions". The underlying goal of this study is to assess PBR-111 positron emission tomography (PET) imaging as a tool to detect microglial activation in the brain of Alzheimer disease (AD) research participants and age- and gender-matched healthy volunteers.
What is the current status of trial NCT01209156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01209156?
The interventions under investigation include: [18F] PBR111 (DRUG).
Who is sponsoring clinical trial NCT01209156?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.